Table 3 Adverse events
From: A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome
Adverse Event(s) | Rivaroxaban-related? (n=) | Rivaroxaban discontinued? (n=) |
|---|---|---|
Infectious (Influenza, respiratory tract, fever NYD, cellulitis, pneumosepsis, disseminated histoplasmosis, viral infection NOS) n=9 | n=0 | n=1 |
Gastrointestinal (Nausea, melena, colonoscopy, 20 lb weight gain, epigastric pain) n=8 | n=2 | n=1 |
Headache n=5 | n=4 | n=2 |
Dermatological (Rash, finger nodules, leg ulcer) n=4 | n=1 | n=2 |
Neurological (Peripheral neuropathy/CNS impairment NYD, Bell’s palsy) n=3 | n=0 | n=0 |
SLE flare (including class IV lupus nephritis) n=2 | n=0 | n=1 |
Other (Chest pain, broken tooth, right hip arthroplasty, back pain, depression, cough, post-thrombotic syndrome, felt unwell, joint pain, prostate cancer, hypertensive urgency, SOB NYD) n=10 | n=0 | n=2 |
Death (Pneumosepsis) n=1 | n=0 | N/A |